Anzeige
Mehr »
Montag, 29.09.2025 - Börsentäglich über 12.000 News
Seltene Ausgangslage: Unbekannter Kupfer-Explorer mit spekulativem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
29.09.25 | 11:37
15,900 Euro
+1,27 % +0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
15,75016,05013:26
15,85015,90013:17

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TEVA Aktie jetzt für 0€ handeln
DoDelveInsight Business Research, LLP: TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight760The TL1A inhibitor market is rapidly advancing, driven by significant investments from major biopharmaceutical companies and growing confidence in its potential to transform autoimmune disease...
► Artikel lesen
DoTeva Pharmaceutical Industries Ltd: Teva Releases Q3 2025 Aide Memoire313TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the "Investors" page on its...
► Artikel lesen
DoTeva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025327TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial...
► Artikel lesen
MiUBS hebt Kursziel für Teva Pharm wegen Austedo-Ausblick auf 26 US-Dollar an65
DiBausch, Teva face lawsuit for delay in generic version of Xifaxan15
DiTeva and Medincell's Risperidone LAI Approved in Canada as LONGAVO310Regulatory News: Medincell (Paris:MEDCL): Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI...
► Artikel lesen
DiAlvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?24
DiTruist Securities reiterates Buy rating on Teva Pharma stock, maintains $25 price target8
DiTruist Securities bestätigt "Buy"-Rating für Teva Pharm Aktie und Kursziel von 25 US-Dollar14
DiGoldman Sachs bestätigt Kaufempfehlung für Teva Pharm nach positiven Studiendaten59
DiTeva Pharma stock gets Buy rating from Goldman Sachs on positive drug data18
22.09.Teva Pharm: Langzeitstudie zu Olanzapin-Depot-Injektion zeigt keine Fälle von PDSS46
22.09.Teva's olanzapine LAI shows no PDSS events in long-term trial data18
21.09.Teva Pharm: Langzeit-Olanzapin verursacht in Phase-3-Studie kein Post-Injektions-Syndrom44
21.09.Teva reports no PDSS events with olanzapine LAI in schizophrenia trial4
21.09.Teva Pharmaceutical Industries Ltd: Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction639Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported high...
► Artikel lesen
21.09.Teva Pharmaceutical Industries Ltd: New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed771Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic...
► Artikel lesen
17.09.Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation385Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,...
► Artikel lesen
16.09.Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting395TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025...
► Artikel lesen
16.09.Teva Pharmaceutical Industries Limited (TEVA)'s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy25
Weiter >>
280 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,1